Triphala for Anti-Inflammatory

Research suggests that Triphala possesses meaningful anti-inflammatory properties, supported by a consistent body of preclinical evidence spanning cell-based studies, animal models, and mechanistic investigations. Studies indicate that Triphala reduces key inflammatory markers such as TNF-α, IL-1β, and NF-κB signaling across multiple experimental models, including models of arthritis, retinal inflammation, neurodegeneration, and oxidative stress-related injury, with its bioactive polyphenols, tannins, and phenolic acids generally credited as the active drivers of these effects. The evidence base is weighted heavily toward in vitro and animal studies, with multiple reviews characterizing the findings as promising but in need of further clinical validation; the one available randomized controlled trial, conducted in long COVID patients, found that Triphala supplementation combined with exercise did not produce measurable anti-inflammatory benefits beyond exercise alone, introducing an important note of caution about translating preclinical findings to human populations. Overall, the research direction is largely supportive but preliminary, and conclusions about anti-inflammatory efficacy in humans remain limited by the relative scarcity of well-designed clinical trials.